Company intelligence / Profile preview

EnCellX

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

ENCell is a South Korea-based biotech company and CDMO specializing in next-generation stem cell therapies, particularly for rare neuromuscular diseases. Its lead candidate, EN001, is in Phase 1b/2a clinical trials for Charcot-Marie-Tooth disease type 1A and Phase 1b/2a trials for Duchenne muscular dystrophy, with preclinical data showing potential for nerve and muscle regeneration[2][3]. The company operates GMP-compliant manufacturing facilities and has secured strategic partnerships for Asian market expansion[2][3].

Therapeutic areas: NeurologyMetabolic DisordersRare Diseases
Modalities: Stem cell therapy
Industry: Biotech

Partnerships

Lucy Biotech: Licensing and strategic alliance for EN001 development and commercialization in Hong Kong, Taiwan, Macau, Vietnam, Thailand, and Singapore (Commercialization and R&D)

Beyond the preview

Go deeper on EnCellX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EnCellX.

Explore the full profile